Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality after Allogeneic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients with Hematological Diseases
Vulnerable patients as defined by one or more of the following criteria
.Aged 65 years or older
.Having Hematopoietic Cell Transplantation - Comorbidity Index (HCT-CI) scores of >= 3
.Having frailty as determined by walk speed of
Patients considered or referred for allogeneic HCT to treat a hematological malignant or non-malignant disease
Able to speak and read English - interaction with the interventionist trainer and endpoint measurement must occur in English
Willing and able to provide informed consent
Stated willingness to comply with study procedures and reporting requirements
Planned allogeneic HCT within 3 weeks - all types of donors and all sorts of conditioning regimens are allowed. Patients with suspected active disease (relatively old disease staging or relatively old intervention) or significant comorbidity (e.g. suspicious untreated pulmonary nodules) based on prior evaluations, that could delay the transplant would be considered for enrollment within a tighter window (10-14 days before allogeneic HCT) to allow for completed pre-HCT work-up evaluations that would confirm readiness to proceed with transplant
Able to exercise at low to moderate intensity
Adequate cardiopulmonary reserve, as judged by self-reported ability to walk up one flight of stairs, no need for supplemental oxygen, and/or physician judgment
Other eligibility criteria may apply.
Other exclusion criteria may apply.